Keyword: Samsung BioLogics
Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.
South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.
China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.
Samsung BioLogics lost almost $6 billion in market value after South Korean securities regulators said the company broke accounting rules.
Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.
GSK is asked for more about its China bribery scandal, AZ made two health-tech deals in China, Samsung BioLogics' reported sales growth.
South Korea’s Samsung BioLogics reported a 56% jump in sales to $420 million (KRW 459.8 billion) for 2017, which the company attributes to boosts from two of its manufacturing facilities.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.